ClinicalTrials.Veeva

Menu
A

Alliance Clinical Trials | Waterloo, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
JNJ-77242113
Upadacitinib
CTP-543
Adalimumab
TAK-279
Povorcitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 13 total trials

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PR...

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Rocatinlimab

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo
Locations recently updated

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Enrolling
NonSegmental Vitiligo
Drug: Placebo
Drug: Povorcitinib

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.

Enrolling
Atopic Dermatitis
Combination Product: Rocatinlimab AI
Combination Product: Rocatinlimab Prefilled Syringe

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

Trial sponsors

Amgen logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Concert Pharmaceuticals logo
Incyte logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems